Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
ProShares UltraShort Nasdaq Biotechnology (BIS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: BIS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type ETF | Historic Profit -30.67% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Volume (30-day avg) 12447 | Beta -1.28 | 52 Weeks Range 13.65 - 20.29 | Updated Date 03/28/2025 |
52 Weeks Range 13.65 - 20.29 | Updated Date 03/28/2025 |
Upturn AI SWOT
ProShares UltraShort Nasdaq Biotechnology
ETF Overview
Overview
ProShares UltraShort Nasdaq Biotechnology (BIS) seeks daily investment results, before fees and expenses, that correspond to two times the inverse (opposite) of the daily performance of the Nasdaq Biotechnology Index. It provides leveraged inverse exposure to the biotechnology sector.
Reputation and Reliability
ProShares is a well-known provider of leveraged and inverse ETFs with a solid track record.
Management Expertise
ProShares has extensive experience in managing leveraged and inverse ETFs.
Investment Objective
Goal
To deliver two times the inverse (opposite) of the daily performance of the Nasdaq Biotechnology Index.
Investment Approach and Strategy
Strategy: Leveraged inverse strategy; aims to magnify the *opposite* daily returns of the Nasdaq Biotechnology Index through the use of derivatives.
Composition Primarily holds derivatives such as swap agreements to achieve its leveraged inverse exposure.
Market Position
Market Share: BIS holds a noticeable, but niche, position within the leveraged inverse biotechnology ETF space.
Total Net Assets (AUM): 62585000
Competitors
Key Competitors
- LABD
- DRUG
Competitive Landscape
The leveraged and inverse biotech ETF space is relatively small and competitive. BIS offers a -2x daily inverse exposure which attracts investors seeking significant short-term gains or hedging strategies. LABD offers a 3x leveraged long position, catering to a different investment thesis. DRUG offers focused exposure, and all are subject to decay.
Financial Performance
Historical Performance: Historical performance data should be evaluated over short periods due to the leveraged nature of the ETF. Due to leverage, long-term returns can be very different from -2x the benchmark.
Benchmark Comparison: Performance should be compared to -2x the daily returns of the Nasdaq Biotechnology Index.
Expense Ratio: 0.95
Liquidity
Average Trading Volume
The average daily trading volume for BIS is moderately high, generally indicating sufficient liquidity.
Bid-Ask Spread
The bid-ask spread is typically low, suggesting efficient trading.
Market Dynamics
Market Environment Factors
Performance is heavily influenced by news and sentiment in the biotechnology sector, broader market trends, and interest rate changes, with heightened impacts due to the 2x leverage.
Growth Trajectory
Growth is driven by investor demand for shorting biotechnology stocks and using the fund for hedging. The growth and holdings will change based on the market sentiment towards biotech.
Moat and Competitive Advantages
Competitive Edge
BIS's primary advantage lies in its -2x leveraged inverse exposure to the Nasdaq Biotechnology Index. This precise leverage target caters to traders seeking amplified short-term gains from anticipated declines in the biotech sector. The ETF provides a tool to quickly capitalize on perceived overvaluation or negative catalysts within the biotechnology industry. However, this strategy is prone to volatility and erosion of value over extended periods.
Risk Analysis
Volatility
BIS is highly volatile due to its leveraged nature, making it suitable only for risk-tolerant investors.
Market Risk
The underlying assets (biotechnology stocks) are subject to significant market risk, regulatory risk, and clinical trial failure risk, amplified by the leverage.
Investor Profile
Ideal Investor Profile
Sophisticated investors and active traders who understand the risks associated with leveraged inverse ETFs and have a short-term investment horizon.
Market Risk
Best suited for active traders seeking short-term tactical exposure to the biotechnology sector. Not suitable for long-term investors.
Summary
ProShares UltraShort Nasdaq Biotechnology (BIS) is a leveraged inverse ETF designed for sophisticated investors seeking to profit from short-term declines in the Nasdaq Biotechnology Index. It offers two times the *inverse* of the index's daily performance through derivatives. This strategy is very high risk and prone to erosion over time. BIS is best used for short-term tactical positions, not for long-term investment strategies and should be only used by the traders who fully understands the high risk involved.
Similar Companies
- LABD
- XBI
- IBB
- DRUG
Sources and Disclaimers
Data Sources:
- ProShares Website
- SEC Filings
- Morningstar
- Yahoo Finance
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and due diligence. Leveraged and inverse ETFs are high-risk investments and are not suitable for all investors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProShares UltraShort Nasdaq Biotechnology
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.